Anocca key facts
as of Oct 2026- Developer of drugs and immunotherapies intended to unlock the therapeutic potential of T-cell immunity.
- Anocca is valued at approximately $110.2M as of Oct 2026 (last reported valuation).
- It has raised $210.6M; the latest was Later Stage VC ($45.8M) in Aug 2025.
- Notable investors include European Union, Nidoco, Ramsbury Invest, AMF, Harald Mix — 9 tracked in total.
- Status: Privately Held (backing).
Anocca's last reported valuation, May 2023. Nothing priced has surfaced since.
- ·Watch Anocca: the Monday email on marks, rounds and moves
Anocca funding rounds
No funding rounds for Anocca are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Anocca valuation
Anocca's last reported valuation was $110 million in May 2023. No priced round, secondary trade or fund mark has surfaced since.
Anocca investors
9 investors are on record for Anocca, including European Union, Nidoco, Ramsbury Invest and AMF.
About Anocca
Developer of drugs and immunotherapies intended to unlock the therapeutic potential of T-cell immunity. The company does precise analysis of T-cell biology that is required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas, including cancer, helping the life sciences sector to develop a range of therapies and vaccination strategies.
- Sector
- Healthcare
- HQ
- Sodertalje, Sweden
- Founded
- 2014
- Employees
- 100
- Website
- anocca.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.